- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00798577
Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Texas
-
Fort Worth, Texas, United States, 76134
- Contact Alcon Call Center for Trial Locations
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Diagnosis in one or both eyes of bacterial conjunctivitis based on:
- symptoms less than or equal to 24 hours prior to first visit
- rating > or equal to 1 for bulbar conjunctival injection
- must have a rating > 1 for conjunctival discharge / exudate in at least one eye (the same eye as bulbar conjunctival injection ) at Visit 1, and
- Must experience some matting in the affected eye(s).
- 1 year of age or older, of any race and either sex
- Able to understand and sign an informed consent that has been approved by an Institutional Review Board; or if the subject is a minor, the informed consent must be signed and understood by the subjects legally authorized representative (parent or guardian). Assent to participate should be obtained from subjects 6 years of age or older unless not allowed by local regulation.
- Must agree to comply with study visit schedule, photographs and other study requirements. If subject is a minor, the parent or guardian must agree to ensure compliance.
Exclusion Criteria:
- Cannot have had bacterial conjunctivitis as reported by subject (or parent if subject is a minor) for > 24 hours.
- Any current lid disease on clinical examination.
- Known or suspected allergy or hypersensitivity to fluoroquinolones.
- Suspected fungal, viral (e.g. Herpes simplex) or Acanthamoeba infection, based on clinical observation.
- Any systemic or ocular disease or disorder, complicating factors or structural abnormality that would negatively affect the conduct or outcome of the study (e.g., hepatitis, acute or chronic renal insufficiency).
- Use of topical ocular medications during the study period.
- Antibiotics (systemic or topical) may not be used within 7 day of visit 1 or anytime after this visit for the duration of the study.
- Women of childbearing potential not using reliable means of birth control.
- Women who are pregnant or lactating.
- Enrollment of more than one person per household at the same time.
- Enrollment of the investigator or his or her staff, family members of the investigator, family members of the investigator's staff, or individuals living in the households of these individuals.
- Participation in any investigational drug or device study within 30 days of entering this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vigamox
Vigamox Ophthalmic Solution (Moxifloxacin 5mg/mL)
|
Moxifloxacin 5mg/mL 3 times daily for 7 days
|
Placebo Comparator: BSS Placebo
Balanced Salt Solution
|
Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory Outcomes From Digital Photography
Time Frame: 24 hours after administration of first dose
|
Photographs were taken before and after treatment.
Outcome is the number of patients whose photographs showed a subjective visual change based upon an exploratory review of patient photographs in signs of bacterial conjunctivitis before and after treatment.
|
24 hours after administration of first dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory Evaluation of Changes in Ocular Signs and Symptoms
Time Frame: Baseline (Day 1) to Day 2
|
Number of patients who had clinical resolution (0 on all scales below) from baseline (Day 1) to Day 2 in ocular and symptoms of bacterial conjunctivitis: Bulbar Conjunctival Injection - 0 (none) to 4 (Severe) scale. Conjunctival Discharge (Mucopurulent) - 0 (none) to 3 (Severe) scale. Lid Erythema - 0 (none) to 3 (Severe) scale. Lid Swelling - 0 (none) to 3 (Severe) scale. Palpebral Conjunctiva - 0 (none) to 3 (Severe) scale. Foreign Body Sensation - 0 (none) to 3 (Severe) scale. Tearing - 0 (none) to 3 (Severe) scale. Photophobia - 0 (none) to 3 (Severe) scale. |
Baseline (Day 1) to Day 2
|
Microbiological Culture Evaluation/Eradication Percent - Enterobacter Faecalis and Candida Albicans
Time Frame: 24 hours after administration of first dose
|
Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1
|
24 hours after administration of first dose
|
Microbiological Culture Evaluation/Eradication Percent - Eradication of All Other Isolates and Corynform-like
Time Frame: 24 hour after administration of first dose
|
Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1
|
24 hour after administration of first dose
|
Microbiological Culture Evaluation/Eradication Percent - Staphylococcus Aureus, Steptococcus Pneumoniae, and Enterobacter Cloacae
Time Frame: 24 hours after administration of first dose
|
Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1
|
24 hours after administration of first dose
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMA-08-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Conjunctivitis
-
Laboratoires TheaCompletedPurulent Bacterial ConjunctivitisFrance
-
IVIEW Therapeutics Inc.CompletedAcute Bacterial ConjunctivitisChina
-
Bausch & Lomb IncorporatedCompletedAcute Bacterial Conjunctivitis
-
Bausch & Lomb IncorporatedCompletedAcute Bacterial Conjunctivitis
-
Azidus BrasilUnknownAcute Bacterial ConjunctivitisBrazil
-
ShireCompletedBacterial ConjunctivitisUnited States, Australia, Austria, Israel, Poland, Hungary, South Africa, Canada, Estonia, France, Italy, Spain, Puerto Rico
-
AllerganCompletedBacterial ConjunctivitisUnited States, India
-
Beijing Tongren HospitalZhuhai Essex Bio-Pharmaceutical Company Limited; Panacea TechnologiesUnknownBacterial ConjunctivitisChina
-
Merck Sharp & Dohme LLCCompletedBacterial ConjunctivitisUnited States
-
Alcon ResearchWithdrawn
Clinical Trials on Vigamox Ophthalmic Solution
-
AllerganCompletedAnti-biotic ResistanceUnited States, Canada
-
Merck Sharp & Dohme LLCCompletedBacterial Infections | Eye Infections | Cataract ExtractionUnited States
-
Laboratorios Sophia S.A de C.V.WithdrawnConjunctivitis, Allergic | Seasonal Allergic Conjunctivitis | Ocular Itching | Ocular Allergy | Perennial Allergic ConjunctivitisMexico
-
Aldeyra Therapeutics, Inc.CompletedAllergic ConjunctivitisUnited States
-
Aldeyra Therapeutics, Inc.Completed
-
Alcon ResearchCompletedOcular Hypertension | Open-angle Glaucoma
-
Cornea Consultants Of NashvilleBausch & Lomb Incorporated; SCRI Development Innovations, LLCTerminatedCorneal UlcersUnited States
-
Santen Pharmaceutical Co., Ltd.CompletedPrimary Open Angle Glaucoma | Ocular HypertensionJapan
-
Aldeyra Therapeutics, Inc.Completed